<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ding P</submitter><funding>Natural Science Foundation of Anhui Province (Anhui Provincial Natural Science Foundation)</funding><funding>University Natural Science Research Project of Anhui Province (Anhui Provincial Universities Natural Science Research Project)</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>314</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936196</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>Hepatocellular carcinoma (HCC) is a highly lethal malignancy, with epithelial-mesenchymal transition (EMT)-driven metastasis a key factor for poor prognosis. The C5a/C5a receptor (C5aR) pathway significantly facilitates HCC cell EMT, yet no approved anti-cancer drugs specifically target C5aR. LukS-PV, a component of Staphylococcus aureus-secreted Panton-Valentine leukocidin (PVL), specifically targets C5aR and exerts anti-tumor effects in hematological and solid tumors. However, its impact on HCC EMT and mechanisms remains unknown. Our study showed LukS-PV targets C5aR to inhibit HCC cell EMT, migration, invasion, and in vivo lung metastasis. Mechanistically, LukS-PV downregulates B-cell lymphoma 6 (BCL6), reducing histone deacetylase 6 (HDAC6) expression. Decreased HDAC6 increases heat sh</pubmed_abstract><journal>Communications biology</journal><pubmed_title>LukS-PV targeting C5aR inhibits EMT in hepatocellular carcinoma via the BCL6/HDAC6/HSPD1 axis.</pubmed_title><pmcid>PMC12936196</pmcid><funding_grant_id>81972001</funding_grant_id><funding_grant_id>82203436</funding_grant_id><funding_grant_id>2208085QH250</funding_grant_id><funding_grant_id>2023AH053403</funding_grant_id><funding_grant_id>82102478</funding_grant_id><pubmed_authors>Shi L</pubmed_authors><pubmed_authors>Nie Z</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Ding P</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Dai Y</pubmed_authors><pubmed_authors>Lu B</pubmed_authors><pubmed_authors>Liu G</pubmed_authors><pubmed_authors>Chang W</pubmed_authors></additional><is_claimable>false</is_claimable><name>LukS-PV targeting C5aR inhibits EMT in hepatocellular carcinoma via the BCL6/HDAC6/HSPD1 axis.</name><description>Hepatocellular carcinoma (HCC) is a highly lethal malignancy, with epithelial-mesenchymal transition (EMT)-driven metastasis a key factor for poor prognosis. The C5a/C5a receptor (C5aR) pathway significantly facilitates HCC cell EMT, yet no approved anti-cancer drugs specifically target C5aR. LukS-PV, a component of Staphylococcus aureus-secreted Panton-Valentine leukocidin (PVL), specifically targets C5aR and exerts anti-tumor effects in hematological and solid tumors. However, its impact on HCC EMT and mechanisms remains unknown. Our study showed LukS-PV targets C5aR to inhibit HCC cell EMT, migration, invasion, and in vivo lung metastasis. Mechanistically, LukS-PV downregulates B-cell lymphoma 6 (BCL6), reducing histone deacetylase 6 (HDAC6) expression. Decreased HDAC6 increases heat sh</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-16T21:54:54.657Z</modification><creation>2026-07-12T03:06:41.466Z</creation></dates><accession>S-EPMC12936196</accession><cross_references><pubmed>41618093</pubmed><doi>10.1038/s42003-026-09640-9</doi></cross_references></HashMap>